Currently Viewing:
Newsroom
Currently Reading
FDA Advisory Committee Confirms Support for Biosimilars to Trastuzumab, Bevacizumab
July 13, 2017 – Surabhi Dangi-Garimella, PhD
Abbott, Bigfoot Biomedical to Partner on Automated Diabetes Management System
July 13, 2017 – Mary Caffrey
ICER Draft Report Assesses Value of 3 PARP Inhibitors for Ovarian Cancer
July 13, 2017 – Christina Mattina
Study Suggests New Vaccine Can Lower Cholesterol, Immunize Against CVD
July 13, 2017 – Alison Rodriguez
Novartis' CAR-T Therapy, CTL019, Approved 10-0 by FDA's ODAC
July 12, 2017 – Surabhi Dangi-Garimella, PhD
Dexcom, Ascensia Reach Deal for Medicare Diabetes Bundle
July 12, 2017 – Mary Caffrey
FDA Grants Full Approval, Expands Indications for Blinatumomab in ALL
July 12, 2017 – Christina Mattina
Genome Sequencing Reveals Rare Disease Risk in 1 of 5 Generally Healthy Adults
July 12, 2017 – Laura Joszt
Novartis' CAR-T Therapy for Pediatric Leukemia to Face FDA Advisory Panel
July 11, 2017 – Alison Rodriguez

FDA Advisory Committee Confirms Support for Biosimilars to Trastuzumab, Bevacizumab

Surabhi Dangi-Garimella, PhD
The comittee voted 17-0 in favor of the Amgen/Allergan bevacizumab biosimilar candidate, ABP 215, and 16-0 in favor of Mylanís trastuzumab biosimilar candidate, MYL-1401O.
A 17-0 vote in favor of the Amgen/Allergan bevacizumab biosimilar candidate, ABP 215, and a 16-0 vote in favor of Mylan’s trastuzumab biosimilar candidate, MYL-1401O—that was the final tally following a vote by the FDA’s Oncologic Drugs Advisory Committee (ODAC) on 2 pioneer biosimilar candidates for cancer treatment.

Both the reference drugs, trastuzumab (Herceptin) and bevacizumab (Avastin), are manufactured by Roche and are blockbusters in their own right: both drugs together brought in $5.6 billion in sales in 2016. Bevacizumab is indicated for the treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous non–small cell lung cancer (NSCLC), metastatic carcinoma of the colon or rectum, metastatic renal cell carcinoma, and other region-specific indications. Trastuzumab is indicated for the treatment of HER2-positive breast cancer, following surgery and for metastatic disease as well as for gastric cancer.

In a briefing document released prior to today’s meeting, the ODAC committee members stated that the “totality of evidence” submitted by Amgen showed that the lung cancer data can be extrapolated to other indications of bevacizumab. This was following evaluation of phase 3 data from the company, which showed the biosimilar candidate had similar safety and immunogenicity as the reference product in patients with NSCLC. However, a few ODAC members did raise concerns over extrapolating data from studies conducted in a single disease to multiple indications.

In a release prior to the beginning of the day’s proceedings, David Nicholson, chief R&D officer at Allergan, said, “ABP 215 is the first product of our collaboration with Amgen to reach this important milestone. If approved, ABP 215 has the potential to provide another high-quality treatment option for cancer patients and pave the way for additional high quality oncology biosimilars from Allergan and Amgen.”

ABP 215 has a Biosimilar User Fee Act (BsUFA) date of September 14, while the BsUFA for MYL-1401O is September 3.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up